Denali Therapeutics Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant to the…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Davis Polk Advises InflaRx N.V. on Its Initial Public Offering
Davis Polk advised InflaRx N.V. on its $100 million initial public offering of 6,667,000 of its common shares. In addition, InflaRx has granted the underwriters a 30-day option to purchase…
Davis Polk Advises McKesson Corporation on Its Acquisition of RxCrossroads from CVS Health Corporation
Davis Polk is advising McKesson Corporation on its acquisition of RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health…
Allena Pharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of Allena Pharmaceuticals, Inc., at $14.00 per share, for total gross…
Ablynx NV $230 Million U.S. Initial Public Offering of ADSs and Listing on the NASDAQ
Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230 million of its ordinary shares in the form of American Depositary…
Deciphera Pharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,500,000 shares of common stock of Deciphera Pharmaceuticals, Inc., at $17.00 per share, for total…
Zai Lab Limited Initial Public Offering and NASDAQ Listing
Davis Polk advised the joint book-running managers and representatives of the underwriters on the $172.5 million initial public offering by Zai Lab Limited of 9,583,333 American…
Davis Polk Advises PharMerica on Its Acquisition by KKR and Walgreens
Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. as a minority…
Sienna Biopharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of Sienna Biopharmaceuticals, Inc., including shares sold pursuant to…
Kala Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The…